



Exchange and Medicare formulary changes effective 8/15/2025

Pharmacy Benefit Additions (these apply to Exchange only):

Crenessity (crinecerfont) – Pharmacy benefit, Non preferred brand, PA

Tryngolza (olezarsen) – Pharmacy benefit, Non preferred brand, PA

Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor) – Pharmacy benefit, Non preferred brand, PA

Gomekli (mirdametinib) – Pharmacy benefit, Non preferred brand, PA

Journavx (suzetrigine) – Pharmacy benefit, Non formulary

Vyalev (foscarnidopa and foslevodopa) – Pharmacy benefit, Non preferred brand, PA

Pharmacy Benefit Changes (these apply to Exchange only):

Fabhalta (iptacopan) – Pharmacy benefit, Criteria update, New indication IgAN and Complement 3 Glomerulopathy

Caplyta (lumateperone) – Pharmacy benefit, Criteria update, New indication Bipolar Depression

Tremfya (guselkumab) – Pharmacy benefit, Criteria update, New indication Crohn's disease

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Imaavy (nipocalimab-aahu) – Medical benefit, PA

Osenvelt (denosumab-bmwo) – Medical benefit, PA

Stoboclo (denosumab-bmwo) – Medical benefit, PA

Tecentriq (atezolizumab) – Medical benefit, Add to Enhanced Oncology Value program

Erbix (cetuximab) – Medical benefit, Add to Enhanced Oncology Value program

Pemetrexed – Medical benefit, Add to Enhanced Oncology Value program

Imfinzi (durvalumab) – Medical benefit, Add to Enhanced Oncology Value program

Imjudo (tremelimumab-actl) – Medical benefit, Add to Enhanced Oncology Value program

Kyprolis (carfilzomib) – Medical benefit, Add to Enhanced Oncology Value program